DexCom, Inc. (DXCM) EPS Basic: 2.34
Is DexCom, Inc.’s EPS basic high or low?
DexCom, Inc.'s EPS basic of 2.34 is 80% above its 5-year average of 1.30, near the high end of its 5-year range (0.56–2.14).
The EPS basic for DexCom, Inc. (DXCM) is 2.34. It is above its 12-month average by 30.00% (1.80).
DXCM EPS Basic Chart
DXCM Average EPS Basic Chart
DXCM Current vs Average EPS Basic Chart
DXCM EPS Basic Metrics
EPS BASIC
2.34
EPS BASIC AVG TTM
1.80
EPS BASIC AVG 3Y
1.48
EPS BASIC AVG 5Y
1.30
EPS BASIC AVG 10Y
0.65
EPS BASIC AVG 15Y
0.40
EPS BASIC AVG 20Y
0.21
CURRENT VS TTM AVG
+30.00%
CURRENT VS 3Y AVG
+58.11%
CURRENT VS 5Y AVG
+80.23%
CURRENT VS 10Y AVG
+258.50%
CURRENT VS 15Y AVG
+485.41%
CURRENT VS 20Y AVG
+1023.07%
DexCom, Inc. EPS Basic Formula & Definition
EPS Basic is earnings per common share before the effect of potentially dilutive securities. It shows how much profit is attributable to each current common share.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. EPS Basic FAQ
- What is the EPS basic for DexCom, Inc. (DXCM)?
- The EPS basic for DXCM stock is 2.34.
- Is DexCom, Inc.'s EPS basic high or low?
- DexCom, Inc.'s EPS basic of 2.34 is 80% above its 5-year average of 1.30, near the high end of its 5-year range (0.56–2.14).
- What is the TTM average EPS basic for DexCom, Inc. (DXCM)?
- The TTM average EPS basic for DXCM stock is 1.80.
- What is the 3Y average EPS basic for DexCom, Inc. (DXCM)?
- The 3Y average EPS basic for DXCM stock is 1.48.
- What is the 5Y average EPS basic for DexCom, Inc. (DXCM)?
- The 5Y average EPS basic for DXCM stock is 1.30.
- What is the 10Y average EPS basic for DexCom, Inc. (DXCM)?
- The 10Y average EPS basic for DXCM stock is 0.65.
- What is the 15Y average EPS basic for DexCom, Inc. (DXCM)?
- The 15Y average EPS basic for DXCM stock is 0.40.
- What is the 20Y average EPS basic for DexCom, Inc. (DXCM)?
- The 20Y average EPS basic for DXCM stock is 0.21.
DexCom, Inc. EPS Basic History
| DATE | EPS BASIC |
|---|---|
| 2025-12-31 | 2.14 |
| 2024-12-31 | 1.46 |
| 2023-12-31 | 1.44 |
| 2022-12-31 | 0.88 |
| 2021-12-31 | 0.56 |
| 2020-12-31 | 1.31 |
| 2019-12-31 | 0.28 |
| 2018-12-31 | -0.36 |
| 2017-12-31 | -0.15 |
| 2016-12-31 | -0.20 |
| 2015-12-31 | -0.18 |
| 2014-12-31 | -0.07 |
| 2013-12-31 | -0.10 |
| 2012-12-31 | -0.20 |
| 2011-12-31 | -0.17 |
| 2010-12-31 | -0.24 |
| 2009-12-31 | -0.30 |
| 2008-12-31 | -0.47 |
| 2007-12-31 | -0.41 |
| 2006-12-31 | -0.43 |
| 2005-12-31 | -0.41 |
| 2004-12-31 | -1.53 |
| 2003-12-31 | -1.14 |
| 2002-12-31 | -0.94 |
| 2001-12-31 | -0.83 |
| 2000-12-31 | -0.57 |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach